Navitoclax is a Bcl-2/Bcl-XL/Bcl-w inhibitor with clinical activity in CLL [47] and recent clinical studies [30, 31] suggest that combinations of BH3 mimetics and inhibitors of BCR signaling are effective in CLL. Here, BCR is linked to B-cell chronic lymphocytic leukemia.